Clinical Trial: Familial Aggregation of Barrett's Esophagus


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Sponsored by:	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by:	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

This research study is trying to determine whether Barrett's esophagus and associated esophageal cancers, specifically esophageal adenocarcinoma are inherited in certain families. Persons who are affected with Barrett's esophagus or esophageal cancer (adenocarcinoma type) are asked to complete a questionnaire that determines their habits and asks a detailed family history. Family members of patients seen at University Hospitals of Cleveland are also being recruited for screening tests of their esophagus. The investigators plan to eventually screen family members at all participating institutions. This research will eventually lead to the identification of inherited genetic changes that cause Barrett's esophagus and esophageal cancer. It will help the investigators develop better methods for preventing or identifying esophageal cancer at an early curable stage.

Condition
Barrett's Esophagus Esophageal Neoplasm

Study Type: Observational
Study Design: Screening, Cross-Sectional, Defined Population, Retrospective/Prospective Study

Genders Eligible for Study: Both

Accepts Healthy Volunteers

Eligible cases will be defined as those patients and their family members who meet the following criteria:

Barrett’s esophagus confirmed by review of pathology and endoscopy report or adenocarcinoma of the esophagus or family members of person with Barrett's esophagus or adenocarcinoma of the esophagus.
Male or female age 18 or older at time of enrollment or male or female less than 18 years of age at time of enrollment with parental consent.
Ability to give informed consent, if patient is age 18 or older.
No history of radiation to the chest or abdomen.
No history of chemotherapy in the year preceding the initial diagnosis of Barrett’s esophagus or esophageal adenocarcinoma.

Amitabh Chak, MD 216-844-5386 axc22@po.cwru.edu

Ohio
University Hospitals of Cleveland, Cleveland, Ohio, 44106-8066, United States; Recruiting

Amitabh Chak, MD 216-844-5386 axc22@po.cwru.edu
Wendy Brock, RN 216-844-3853 wendy.brock2@uhhs.com
Amitabh Chak, MD, Principal Investigator

Ohio State University, Columbus, Ohio, United States; Recruiting

Charis Eng, MD, PhD 614-292-2347 eng-1@medctr.osu.edu
Carrie Drovdlic, MS 614-293-9058 drovdlic-1@medctr.osu.edu
Charis Eng, MD, PhD, Principal Investigator

Cleveland Clinic Foundation, Cleveland, Ohio, United States; Recruiting

Gary Falk, MD 216-444-1762 falkg@ccf.org
Janine Bauman, RN 216-444-6526 jbauman@ccf.org
Gary Falk, MD, Principal Investigator

Tennessee
Vanderbilt University Medical Center, Nashville, Tennessee, United States; Recruiting

William Grady, MD 615-322-4207 william.grady@mcmail.vanderbilt.edu
Amy Crunk, MS 615-343-8582 amy@phg.mc.vanderbilt.edu
William Grady, MD, Principal Investigator

Study ID Numbers: FABE
Record last reviewed: October 2004
Record first received: April 14, 2003
ClinicalTrials.gov Identifier: NCT00058877
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-08